News
Biocon enters commercialization agreement with Zentiva
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
- By IPP Bureau
| November 24, 2022
Biocon Limited, an innovation-led global biopharmaceutical company, has announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe. Biocon will also retain the right to commercialize this product under its own brand in the region.
Zentiva has a strong legacy in branded generics across several therapeutic areas, including diabetes, cardiology, respiratory and oncology. With a committed focus on research and development, and four flagship manufacturing facilities in Bucharest, Prague, and Ankleshwar, Zentiva is rapidly expanding its reach in Europe and beyond.
Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd. said, “We are pleased to build upon our existing relationship with Zentiva for the commercialization of this complex drug product in the European markets. We look forward to leveraging our mutual strengths to achieve a common objective of creating affordable access to complex generic medicines.”
Abhijit Zutshi, Global Commercial Head - Generic Formulations, Biocon Ltd. said, “This partnership will help Biocon to achieve its strategic objective of expanding its footprint in the European market, underpinning our commitment to providing high-quality, affordable medicines to patients around the globe.
_256_275.jpg)
.jpg)
